SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
YM BioSciences: Trading Below Cash with Multiple Catalysts
AMGN
|
|
|
-7.32%
in
106 days
YM BioSciences (AMEX:YMI) (TSE:YM) (US$0.58) currently trades at a negative enterprise value of about $10 million (M), which includes $43M in cash, zero debt, and a trailing 12-month cash burn rate of about $18M. YMI has about 58.5M shares outstanding and 65M shares of common stock on a fully diluted basis, which equates to a market cap of about US$34M and US$38M, respectively. <o:p> </o:p> http://biomedreports.com/articles/most-popular/5071-ym-biosci... <o:p> </o:p> <> Nimotuzumab (nimo) (an IgG1, humanized epidermal growth factor or EGFR targeting mo...
|
FDA Calendar Updates: Acorda, Amgen, DOR BioPharma
AMGN
|
|
|
-4.77%
in
4 days
(closed on 08/08/09)
Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of 290 entries as of 8/4/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clinical trial result...
|
Amgen 2Q Earnings Beat, Raises Guidance, Denosumab Deal
AMGN
|
|
|
+4.53%
in
8 days
(closed on 08/04/09)
Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS) of $1.29 for 2Q09, an increase of 13% compared to $1.14 for the 2Q08. Adjusted net income increased 6% to $1.3 billion during 2Q09 versus $1.2 billion during 2Q08. Total revenue declined by 1% during 2Q09 to $3.71 billion versus $3.76 billion during 2Q08. The Company provided revenue guidance for 2009 that is trending towards the upper end of its current guidance range of $14.4-14.8 billion. Amgen now expects 2009 adjusted EPS to be in the range of $4.80-4.95, an increase from the previous range of $4.55 to $4.75. The Company no...
|
FDA Calendar: 2H09 Binary Event Trades
AMGN
|
|
|
-0.25%
in
1 day
(closed on 07/27/09)
<> Below is a selection of companies included in the BioMedReports.com FDA Calendar database of 281 entries as of 7/26/09 with expected binary event catalysts through year-end. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the ...
|
FDA Calendar Updates: Amgen, Bayer, Biogen, Noveko, Peplin, Transdel
AMGN
|
|
|
+0.63%
in
18 days
(closed on 07/26/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 246 entries as of 7/8/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending...
|
From the Blogosphere
ImmunoGen’s Second License to Amgen (IMGN, AMGN)
|
|
|
ImmunoGen, Inc. (NASDAQ:IMGN) has announced that Amgen, Inc. (NASDAQ:AMGN)Inc has licensed the exclusive right to use ImmunoGen’s maytansinoid Targeted Antibody Payload (TAP) technology for the development of anticancer therapeutics to an undisclosed ...
|
H&Q Healthcare Investors Closed-End Fund Decently Valued
H&Q Healthcare Investors (HQH) appears to a be a decent value now within the closed-end fund universe. It is broadly diversified, and primarily invests in biotechnology, medical devices, pharmaceuticals and medical delivery. It also invests a limited portion of the portfolio in smaller, emerging companies and some restricted securities. In their last SEC filing (as of June 30), the top five holdings were: Teva (TEVA), Gilead (GILD), Celgene (CELG), Amgen (AMGN) and Biogen (BIIB). <>On August 4, the fund discontinued their managed distribution policy. HQH had been paying out 2% of NAV in capit...
|
Nasdaq Market Wrap 8 November
|
|
|
The 60-minute trend is up according to the force index indicator. %b has printed a slightly negative divergence. Prices last week printed an impressive of 5 cnsecutive up days and now they restesting the rising trendline. 1749 and 1775 the resistance. Support at 1650. Then 1590. Prices are now testing the lower trendline of a channel that prices are forming. AKAM, AMZN, COST, QCOM, SBUX printed new 20-day highs. JAVA printed a 20-day low. EBAY and GILD printed 5 and GOOG 4 consecutive up closes. I remain negative on the market and will need to assess how high this move will continue. ...
|
Nasdaq Market Wrap 8 November
The 60-minute trend is up according to the force index indicator. %b has printed a slightly negative divergence. Prices last week printed an impressive of 5 cnsecutive up days and now they restesting the rising trendline. 1749 and 1775 the resistance. Support at 1650. Then 1590. Prices are now testing the lower trendline of a channel that prices are forming. AKAM, AMZN, COST, QCOM, SBUX printed new 20-day highs. JAVA printed a 20-day low. EBAY and GILD printed 5 and GOOG 4 consecutive up closes. I remain negative on the market and will need to assess how high this move will continue. ...
|
Nasdaq Market Wrap 1 November
The 60-minute trend is down according to the force index indicator. %b has printed a slightly positive divergence. Finally prices have moved quickly to the downside. The Nasdaq is underperforming the Dow and the S&P. In fact, the breakout of the rising trendline has already occurred. On Thursday prices retested the trendline and Friday accelerated to the downsode quite impressively. Support at 1650. Then 1590. Prices are now testing the lower trendline of a channel that prices are forming. I would expect overall a negative week. Many stocks have printed new 20-day low. I remain negative on...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on AMGN |
Visit streetinsider.com
Portfolio results thru 8/8/08
- Portfolio at www.updown.com - started 1/11/08
9.8% return includes dividends and commission.
Started socialpicks on 6/30. some stocks here are not in...
|
Stock update and watch list 7/29/08
- Due to difficulties understanding the socialpicks system regarding changing rating from buy to hold and thus resetting the performance, I wanted to sum...
|
More Resources
|
About Amgen Inc
- Answers.com
